Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Significance of lymph node involvement in local recurrence of colorectal cancer.

Dumont F, Muñoz MA, De Franco V, Wernert R, Verriele V, Heyman MF, Kerdraon O, Capitain O, Guerin-Meyer V, Raimbourg J, Senellart H, Hiret S, Raoul JL, Thibaudeau E.

J Surg Oncol. 2019 Sep;120(4):722-728. doi: 10.1002/jso.25631. Epub 2019 Jul 22.

PMID:
31332806
2.

Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.

Raoul JL, Frenel JS, Raimbourg J, Gilabert M.

Hepat Oncol. 2019 Jun 4;6(1):HEP11. doi: 10.2217/hep-2019-0001. Review.

3.

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report.

Moisset L, Raimbourg J, Hiret S, Dauve J, Boisdron-Celle M, Senellart H, Raoul JL.

Case Rep Oncol. 2019 Jun 5;12(2):426-429. doi: 10.1159/000500857. eCollection 2019 May-Aug.

4.

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E.

JCI Insight. 2019 Jun 13;5. pii: 128180. doi: 10.1172/jci.insight.128180.

5.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
6.

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1414-1423. doi: 10.1097/MEG.0000000000001420.

PMID:
31045613
7.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.

PMID:
30575490
8.

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein.

Gilabert M, Raoul JL.

J Hepatocell Carcinoma. 2018 Nov 2;5:91-98. doi: 10.2147/JHC.S157413. eCollection 2018. Review.

9.

Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes.

Gilabert M, Turrini O, Ewald J, Moureau-Zabotto L, Poizat F, Raoul JL, Delpero JR.

Surg Oncol. 2018 Dec;27(4):619-624. doi: 10.1016/j.suronc.2018.07.014. Epub 2018 Aug 3.

PMID:
30449481
10.

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T.

Cancer Treat Rev. 2019 Jan;72:28-36. doi: 10.1016/j.ctrv.2018.11.002. Epub 2018 Nov 12. Review.

PMID:
30447470
11.

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan 1;30(1):6-8. doi: 10.1093/annonc/mdy471. No abstract available.

PMID:
30358824
12.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

Bachet JB, Lucidarme O, Levache CB, Barbier E, Raoul JL, Lecomte T, Desauw C, Brocard F, Pernot S, Breysacher G, Lagasse JP, Di Fiore F, Etienne PL, Dupuis OJM, Aleba A, Lepage C, Taieb J; for FFCD 1102 investigators.

Eur J Cancer. 2018 Nov;104:108-116. doi: 10.1016/j.ejca.2018.09.006. Epub 2018 Oct 18.

PMID:
30343254
13.

Characterization of subepithelial lesions of the stomach and esophagus by contrast-enhanced EUS: A retrospective study.

Pesenti C, Bories E, Caillol F, Ratone JP, Godat S, Monges G, Poizat F, Raoul JL, Ries P, Giovannini M.

Endosc Ultrasound. 2019 Jan-Feb;8(1):43-49. doi: 10.4103/eus.eus_89_17.

14.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.

Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26. Review.

15.

[Hepatocellular carcinoma: Increase in incidence or future plague?]

Raoul JL, Raimbourg J, Hiret S, Adhoute X, Senellart H.

Bull Cancer. 2018 May;105(5):502-507. doi: 10.1016/j.bulcan.2018.02.003. Epub 2018 Mar 19. Review. French.

PMID:
29567280
16.

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M, Bayle O, Beaurain P, Monnet O, Bourlière M.

Eur J Gastroenterol Hepatol. 2018 Apr;30(4):368-375. doi: 10.1097/MEG.0000000000001082.

PMID:
29384796
17.

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts.

Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, Moutardier V, Turrini O, Giovannini M, Bian B, Bigonnet M, Rubis M, Elarouci N, Armenoult L, Ayadi M, Duconseil P, Gasmi M, Ouaissi M, Maignan A, Lomberk G, Boher JM, Ewald J, Bories E, Garnier J, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Grandval P, Barraud-Blanc M, Norguet E, Gilabert M, Delpero JR, Roques J, Calvo E, Guillaumond F, Vasseur S, Urrutia R, de Reyniès A, Dusetti N, Iovanna J.

Cell Rep. 2017 Nov 28;21(9):2458-2470. doi: 10.1016/j.celrep.2017.11.003.

18.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

19.

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group.

Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.

PMID:
29107679
20.

Using a very low-density SNP panel for genomic selection in a breeding program for sheep.

Raoul J, Swan AA, Elsen JM.

Genet Sel Evol. 2017 Oct 24;49(1):76. doi: 10.1186/s12711-017-0351-0.

21.

Intermediate stage treatment: Is TACE enough?

Adhoute X, Penaranda G, Raoul JL, Bourlière M.

Liver Int. 2018 Jan;38(1):187. doi: 10.1111/liv.13598. Epub 2017 Oct 23. No abstract available.

PMID:
28952186
22.

A 25-gene classifier predicts overall survival in resectable pancreatic cancer.

Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F.

BMC Med. 2017 Sep 20;15(1):170. doi: 10.1186/s12916-017-0936-z.

23.

Response to 'the flexible therapeutic approach to the BCLC B stage': Time for scoring systems?

Adhoute X, Pénaranda G, Sellier F, Raoul JL.

J Hepatol. 2017 Sep 15. pii: S0168-8278(17)32285-7. doi: 10.1016/j.jhep.2017.07.038. [Epub ahead of print] No abstract available.

PMID:
28919471
24.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M.

Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.

PMID:
28911069
25.

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

Raoul JL, Gilabert M, Adhoute X, Edeline J.

Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476. doi: 10.1080/14656566.2017.1378346. Epub 2017 Sep 14. Review.

PMID:
28893090
26.

How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?

Gilabert M, Raoul JL, Rousseau F.

J Geriatr Oncol. 2017 Nov;8(6):407-412. doi: 10.1016/j.jgo.2017.08.007. Epub 2017 Sep 6. Review.

PMID:
28888554
27.

Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.

Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T.

Eur J Cancer. 2017 Oct;84:239-249. doi: 10.1016/j.ejca.2017.07.038. Epub 2017 Aug 19.

PMID:
28829992
28.

Optimal mating strategies to manage a heterozygous advantage major gene in sheep.

Raoul J, Palhière I, Astruc JM, Swan A, Elsen JM.

Animal. 2018 Mar;12(3):454-463. doi: 10.1017/S1751731117001835. Epub 2017 Aug 3.

PMID:
28770690
29.

Prediction of benefit after transarterial chemoembolization (TACE): Subclassifications or scoring systems?

Adhoute X, Penaranda G, Raoul JL, Bourlière M.

Liver Int. 2018 Jan;38(1):184. doi: 10.1111/liv.13516. Epub 2017 Jul 29. No abstract available.

PMID:
28695577
30.

[Patient participation in medical decision-making: From concept to reality in oncology].

Raoul JL, Maraninchi D.

Bull Cancer. 2017 Jul - Aug;104(7-8):695-700. doi: 10.1016/j.bulcan.2017.06.002. Epub 2017 Jul 5. French. No abstract available.

PMID:
28688746
31.

To TACE or not to TACE? Lessons from a negative trial.

Raoul JL, Gilabert M, Adhoute X.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23. No abstract available.

32.

Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.

Gilabert M, Boher JM, Raoul JL, Paye F, Bachellier P, Turrini O, Delpero JR; Association Française de Chirurgie.

Medicine (Baltimore). 2017 Jun;96(24):e7214. doi: 10.1097/MD.0000000000007214.

33.

Hepatocellular Carcinoma: Slow Progress in a Booming Epidemic.

Raoul JL, Gilabert M.

J Oncol Pract. 2017 Jun;13(6):365-366. doi: 10.1200/JOP.2017.024364. No abstract available.

PMID:
28605618
34.

Usefulness of the MESH score in a European hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Bourlière M.

World J Hepatol. 2017 May 28;9(15):711-714. doi: 10.4254/wjh.v9.i15.711.

35.

An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value.

Andriantsoa M, Hoibian S, Autret A, Gilabert M, Sarran A, Niccoli P, Raoul JL.

PLoS One. 2017 May 31;12(5):e0177971. doi: 10.1371/journal.pone.0177971. eCollection 2017.

36.

Development of a SNP panel dedicated to parentage assignment in French sheep populations.

Tortereau F, Moreno CR, Tosser-Klopp G, Servin B, Raoul J.

BMC Genet. 2017 May 26;18(1):50. doi: 10.1186/s12863-017-0518-2.

37.

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M.

World J Gastroenterol. 2017 Apr 14;23(14):2545-2555. doi: 10.3748/wjg.v23.i14.2545.

38.

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.

Gilabert M, Chanez B, Rho YS, Giovanini M, Turrini O, Batist G, Kavan P, Raoul JL.

Medicine (Baltimore). 2017 Apr;96(16):e6544. doi: 10.1097/MD.0000000000006544.

39.

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.

Boisdron-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E.

Semin Oncol. 2017 Feb;44(1):24-33. doi: 10.1053/j.seminoncol.2017.02.007. Epub 2017 Feb 9.

PMID:
28395759
40.

A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.

Chanez B, Bertucci F, Gilabert M, Madroszyk A, Rousseau F, Perrot D, Viens P, Raoul JL.

Support Care Cancer. 2017 Sep;25(9):2715-2722. doi: 10.1007/s00520-017-3680-1. Epub 2017 Mar 28.

PMID:
28353038
41.

Prognostic Value of Molecular Subtypes in Pancreatic Cancer.

Bertucci F, Birnbaum DJ, Finetti P, Gilabert M, Poizat F, Raoul JL, Birnbaum D, Mamessier E.

Pancreas. 2017 Apr;46(4):e29-e31. doi: 10.1097/MPA.0000000000000787. No abstract available.

PMID:
28291163
42.

Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts.

Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, Poizat F, Nicolle R, Blum Y, Marisa L, Rubis M, Raoul JL, Bradner JE, Qi J, Lomberk G, Urrutia R, Saul A, Dusetti N, Iovanna J.

EMBO Mol Med. 2017 Apr;9(4):482-497. doi: 10.15252/emmm.201606975.

43.

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.

Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):706-715. doi: 10.1097/MEG.0000000000000852.

PMID:
28195873
44.

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM.

J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.

45.

Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.

Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL.

Mol Clin Oncol. 2017 Jan;6(1):44-48. doi: 10.3892/mco.2016.1097. Epub 2016 Dec 1.

46.

How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma.

Raoul JL, Adhoute X, Gilabert M, Edeline J.

World J Hepatol. 2016 Dec 18;8(35):1541-1546. doi: 10.4254/wjh.v8.i35.1541. Review.

47.

Use of chemotherapy near the end of life: what factors matter?

Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, Morin L.

Ann Oncol. 2017 Apr 1;28(4):809-817. doi: 10.1093/annonc/mdw654.

PMID:
27993817
48.

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E.

Target Oncol. 2016 Dec;11(6):815-824.

PMID:
27924459
49.

Genetic and economic effects of the increase in female paternal filiations by parentage assignment in sheep and goat breeding programs.

Raoul J, Palhière I, Astruc JM, Elsen JM.

J Anim Sci. 2016 Sep;94(9):3663-3683. doi: 10.2527/jas.2015-0165.

PMID:
27898915
50.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885

Supplemental Content

Support Center